scholarly journals Dendritic Cells in Cord Blood Transplantation: A Review

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Marta Isabel Pereira ◽  
Artur Paiva
Keyword(s):  
Dendritic Cells ◽  
Cord Blood ◽  
Tumor Antigens ◽  
Residual Disease ◽  
Cord Blood Transplantation ◽  
Success Rates ◽  
Innate And Adaptive Immunity ◽  
Blood Transplantation ◽  
Self Tolerance ◽  
Antigen Presenting

Dendritic cells (DCs) are a heterogeneous population of antigen-presenting cells derived from hematopoietic progenitors that bridge the transition between the innate and adaptive immune responses, while maintaining self-tolerance and Th1/Th2 homeostasis, by priming other cells in either an immunogenic or tolerogenic direction. Through their role in both innate and adaptive immunity, DCs play a major part in transplant engraftment and rejection and in graft-versus-host disease (GvHD). Preferentially tolerogenic or immunogenic DC subtypes offer targets for immunotherapy, to optimize transplant success rates and prolong disease-free and overall survival. Cord blood DCs are immature and preferentially tolerogenic, due to maternal-fetal tolerance, leading to better graft acceptance and immune reconstitution and explaining the lower incidence and severity of GvHD in CB transplantation, despite donor-host mismatching. Manipulation of DC maturation and cell loading with tumor-antigens can direct antitumor immunity and target minimal residual disease, as demonstrated for acute myeloid leukemia, optimizing the graft-versus-leukemia effect.

scholarly journals Impact of detectable measurable residual disease on umbilical cord blood transplantation

2020 ◽  
Vol 95 (9) ◽  
pp. 1057-1065 ◽  
Author(s):  
Frédéric Baron ◽  
Myriam Labopin ◽  
Annalisa Ruggeri ◽  
Jorge Sierra ◽  
Stephen Robinson ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Residual Disease ◽  
Cord Blood Transplantation ◽  
Umbilical Cord Blood Transplantation ◽  
Blood Transplantation ◽  
Measurable Residual Disease

The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation

Transfusion ◽  
2007 ◽  
Vol 47 (2) ◽  
pp. 272-279 ◽  
Author(s):  
Araceli Encabo ◽  
Pilar Solves ◽  
Francisco Carbonell-Uberos ◽  
Maria Dolores Miñana
Keyword(s):  
Dendritic Cells ◽  
Cord Blood ◽  
Cord Blood Transplantation ◽  
Blood Transplantation ◽  
Functional Immaturity

scholarly journals Combination of Haploidentical Hematopoietic with Low-Dose TBI and Cord Blood Transplantation for Hematologic Malignancies

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4856-4856
Author(s):  
Shenxian Qian ◽  
Fan Yang ◽  
Pengfei Shi
Keyword(s):  
Cord Blood ◽  
Low Dose ◽  
Conflicts Of Interest ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Cord Blood Transplantation ◽  
Hematologic Malignancies ◽  
Hla Typing ◽  
Blood Transplantation ◽  
Cell Counts

Abstract Objective: To evaluate the efficacy and safety of the combination of haploidentical hematopoietic with low-doseTotal body irradiation（TBI）and cord blood transplantation for hematologic malignancies. Methods: This study was conducted as a retrospective review of medical records of 5 patients with hematologic malignancies who received a combination of haploidentical hematopoietic with low-dose TBI and cord blood transplantation at Affiliated HangZhou first people's hospital of Zhejiang University school of medicine, from March to June 2021. Results: 5 patients were included for the analysis. There were 1 acute myeloid leukemia (AML),2 acute lymphoblastic leukemia (ALL) and 2 Non-Hodgkin's Lymphoma(NHL). The minimal residual disease (MRD) of the two patients with ALL was positive before allo-HCT.Median age of patients at the time of allo-HCT was 30 years (range 21-63 years). All patients received low-dose TBI(4-6GY) +antithymocyte globulin（ATG）based conditioning.Cord blood units were selected based on the results of HLA typing and cell doses evaluated before freezing. Units with at least 4/6 matched HLA loci became the candidates. The median values of absolute total nucleated cell counts were 139.0 (80.8-240.0) × 10 7 / kg in The haploidentical grafts and 2.25 (1.32-3.10)× 10 7 / kg in the cord blood units,respectively. The median doses of CD34+ cells infused were 28.6 (22.0-51.1) × 10 5 / kg in the haploidentical grafts and 1.5 (1.0-3.5)×10 5/kg in the cord blood units, respectively.All patients attained complete engraftment,of which 3 were haploidentical engraftment and 2 were mixed hematopoietic chimerism that included haploidentical and cord blood engraftment.The median time to neutrophil engraftment was 12 (10-22) days and 13 (11-22) days for platelets. All patients were in complete remission with MRD-negetive during a median follow-up of 83 (34-136) days.No patients developed grade II-IV acute graft versus host desease. Conclusion:The results suggested that the combination of haploidentical hematopoietic with low-dose TBI and cord blood transplantation may potentially improve the outcome of HSCT. It offers a transplant alternative for patients with hematologic malignancies who lack matching donors. Disclosures No relevant conflicts of interest to declare.

scholarly journals High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

2020 ◽  
Vol 4 (23) ◽  
pp. 6064-6076
Author(s):  
Juliet N. Barker ◽  
Sean M. Devlin ◽  
Kristine A. Naputo ◽  
Kelcey Skinner ◽  
Molly A. Maloy ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Cord Blood ◽  
Hematopoietic Cell Transplantation ◽  
Residual Disease ◽  
Cord Blood Transplantation ◽  
Human Leukocyte ◽  
Progression Free Survival ◽  
Free Survival ◽  
Cell Dose ◽  
Blood Transplantation

Abstract Cord blood transplantation (CBT) after high intensity or nonmyeloablative conditioning has limitations. We investigated cyclosporine-A/mycophenolate mofetil–based intermediate intensity (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, total body irradiation 400 cGy) unmanipulated double-unit CBT (dCBT) with prioritization of unit quality and CD34+ cell dose in graft selection. Ninety adults (median age, 47 years [range, 21-63]; median hematopoietic cell transplantation comorbidity index, 2 [range, 0-8]; 61 [68%] acute leukemia) received double-unit grafts (median CD34+ cell dose, 1.3 × 105/kg per unit [range, 0.2-8.3]; median donor-recipient human leukocyte antigen (HLA) match, 5/8 [range 3-7/8]). The cumulative incidences of sustained CB engraftment, day 180 grade III-IV acute, and 3-year chronic graft-versus-host disease were 99%, 24%, and 7%, respectively. Three-year transplant-related mortality (TRM) and relapse incidences were 15% and 9%, respectively. Three-year overall survival (OS) is 82%, and progression-free survival (PFS) is 76%. Younger age and higher engrafting unit CD34+ cell dose both improved TRM and OS, although neither impacted PFS. Engrafting unit-recipient HLA match was not associated with any outcome with a 3-year PFS of 79% in 39 patients engrafting with 3-4/8 HLA-matched units. In 52 remission acute leukemia patients, there was no association between minimal residual disease (MRD) and 3-year PFS: MRD negative of 88% vs MRD positive of 77% (P = .375). Intermediate intensity dCBT is associated with high PFS. Use of highly HLA mismatched and unmanipulated grafts permits wide application of this therapy, and the low relapse rates support robust graft-versus-leukemia effects even in patients with MRD.

Sign in / Sign up

Export Citation Format

Share Document